Patents by Inventor Braydon Charles Guild

Braydon Charles Guild has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cleavable lipids
    Patent number: 9717690
    Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: August 1, 2017
    Assignee: RaNA Therapeutics, Inc.
    Inventors: Braydon Charles Guild, Michael Heartlein, Frank DeRosa, Jerry Chi Zhang
  • CFTR mRNA compositions and related methods and uses
    Patent number: 9713626
    Abstract: Pharmaceutical compositions comprising an mRNA-loaded nanoparticle, wherein the mRNA is an in vitro transcribed mRNA and has a coding sequence at least 80% identical to SEQ ID NO: 3, and wherein the mRNA encodes a human cystic fibrosis transmembrane conductance regulator (CFTR) protein comprising the amino acid sequence of SEQ ID NO:1 are provided. The present invention is particularly useful for treating cystic fibrosis.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: July 25, 2017
    Assignees: RaNA Therapeutics, Inc., Ethris GmbH
    Inventors: Michael Heartlein, Braydon Charles Guild, Frank DeRosa, Carsten Rudolph, Christian Plank, Lianne Smith
  • Pulmonary delivery of mRNA
    Patent number: 9597413
    Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: March 21, 2017
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
  • Ionizable cationic lipids
    Patent number: 9546128
    Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: January 17, 2017
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Frank DeRosa, Braydon Charles Guild, Michael Heartlein
  • SYNERGISTIC ENHANCEMENT OF THE DELIVERY OF NUCLEIC ACIDS VIA BLENDED FORMULATIONS
    Publication number: 20160151409
    Abstract: Disclosed herein are pharmaceutical compositions that comprise “blends” of lipid nanoparticles and related methods of using such blended compositions to deliver polynucleotides to one or more target cells, tissues or organs. The blended compositions are generally characterized as being able to efficiently deliver polynucleotides to target cells and by their ability to enhance the expression of such polynucleotides and the production of functional proteins by target cells.
    Type: Application
    Filed: March 14, 2014
    Publication date: June 2, 2016
    Inventors: Frank Derosa, Lianne Smith, Michael Heartlein, Braydon Charles Guild
  • CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES
    Publication number: 20160106772
    Abstract: Materials, formulations, production methods, and methods for delivery of CFTR mRNA for induction of CFTR expression, including in the mammalian lung are provided. The present invention is particularly useful for treating cystic fibrosis.
    Type: Application
    Filed: October 6, 2015
    Publication date: April 21, 2016
    Inventors: Michael Heartlein, Braydon Charles Guild, Frank DeRosa, Carsten Rudolph, Christian Plank, Lianne Smith
  • mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
    Publication number: 20160101160
    Abstract: Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification 5 conferring stability to the RNA, as well as related methods, are disclosed.
    Type: Application
    Filed: May 18, 2015
    Publication date: April 14, 2016
    Inventors: Braydon Charles Guild, Michael Heartlein, Frank DeRosa
  • MRNA therapy for Fabry disease
    Patent number: 9308281
    Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: April 12, 2016
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
  • Compositions and Methods for Antibodies Targeting Complement Protein C5
    Publication number: 20160031975
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Application
    Filed: April 28, 2015
    Publication date: February 4, 2016
    Applicant: NOVARTIS AG
    Inventors: Beate DIEFENBACH-STREIBER, Adina EBERTH, Braydon Charles GUILD, Yong-In KIM, Michael ROGUSKA, Igor SPLAWSKI
  • METHODS AND COMPOSITIONS FOR DELIVERING MRNA CODED ANTIBODIES
    Publication number: 20160031981
    Abstract: The present invention provides, among other things, methods and compositions for delivering an antibody in vivo by administering to a subject in need thereof one or more mRNAs encoding a heavy chain and a light chain of an antibody, and wherein the antibody is expressed systemically in the subject. In some embodiments, the one or more mRNAs comprise a first mRNA encoding the heavy chain and a second mRNA encoding the light chain of the antibody.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Michael Heartlein, Frank Derosa, Anusha Dias, Braydon Charles Guild
  • COMPOSITIONS AND METHODS FOR mRNA DELIVERY
    Publication number: 20150366997
    Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.
    Type: Application
    Filed: December 6, 2013
    Publication date: December 24, 2015
    Applicant: Shire Human Genetics Therapies, Inc.
    Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
  • CFTR mRNA compositions and related methods and uses
    Patent number: 9181321
    Abstract: Materials, formulations, production methods, and methods for delivery of CFTR mRNA for induction of CFTR expression, including in the mammalian lung are provided. The present invention is particularly useful for treating cystic fibrosis.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: November 10, 2015
    Assignees: Shire Human Genetic Therapies, Inc., Ethris GMBH
    Inventors: Michael Heartlein, Braydon Charles Guild, Frank DeRosa, Carsten Rudolph, Christian Plank, Lianne Smith
  • NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
    Publication number: 20150267192
    Abstract: The invention provides, among other things, methods of mRNA stabilizing mRNA and nuclease resistant mRNA prepared in accordance with such methods. In certain embodiments, the nuclease resistant mRNA encodes a functional protein, such as enzyme, and is characterized by its resistance to nuclease digestion, increased half-life and/or its ability to produce increased amounts of the functional protein (e.g., enzyme) encoded thereby.
    Type: Application
    Filed: June 7, 2013
    Publication date: September 24, 2015
    Inventors: Michael Heartlein, Braydon Charles Guild, Frank DeRosa
  • mRNA for use in treatment of human genetic diseases
    Patent number: 9061021
    Abstract: Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification conferring stability to the RNA, as well as related methods, are disclosed.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: June 23, 2015
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Braydon Charles Guild, Michael Heartlein, Frank DeRosa
  • IONIZABLE CATIONIC LIPIDS
    Publication number: 20150166462
    Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.
    Type: Application
    Filed: March 29, 2013
    Publication date: June 18, 2015
    Inventors: Frank DeRosa, Braydon Charles Guild, Michael Heartlein
  • PULMONARY DELIVERY OF MRNA TO NON-LUNG TARGET CELLS
    Publication number: 20150157565
    Abstract: Compositions comprising mRNA formulated for pulmonary administration and related methods for delivery of the mRNA and/or encoded protein to a non-lung cell or tissue. The compositions and methods may be used to prevent or ameliorate the symptoms of diseases associated with the mRNA encoded protein.
    Type: Application
    Filed: June 7, 2013
    Publication date: June 11, 2015
    Inventors: Michael Heartlein, Braydon Charles Guild, Frank DeRosa, Carsten Rudolph, Christian Plank
  • LIPID-DERIVED NEUTRAL NANOPARTICLES
    Publication number: 20150086613
    Abstract: Disclosed herein are novel lipids and liposomal compositions prepared using such compounds and related methods of neutralizing or otherwise modifying such liposomal compositions. The lipids described herein are useful for example, as liposomal vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and the subsequent transfection of such target cells. In certain embodiments, one or more of the compounds that comprise the liposomal delivery vehicle may be neutralized or further modified such that the properties of the liposomal delivery vehicle are modified.
    Type: Application
    Filed: March 29, 2013
    Publication date: March 26, 2015
    Inventors: Frank DeRosa, Braydon Charles Guild, Michael Heartlein
  • CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES
    Publication number: 20150038556
    Abstract: Materials, formulations, production methods, and methods for delivery of CFTR mRNA for induction of CFTR expression, including in the mammalian lung are provided. The present invention is particularly useful for treating cystic fibrosis.
    Type: Application
    Filed: June 17, 2014
    Publication date: February 5, 2015
    Inventors: Michael Heartlein, Braydon Charles Guild, Frank DeRosa, Carsten Rudolph, Christian Plank, Lianne Smith
  • mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
    Publication number: 20150004217
    Abstract: Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification conferring stability to the RNA, as well as related methods, are disclosed.
    Type: Application
    Filed: July 8, 2014
    Publication date: January 1, 2015
    Inventors: Braydon Charles Guild, Michael Heartlein, Frank DeRosa
  • Compositions and methods for antibodies targeting complement protein C5
    Patent number: 8883158
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: November 11, 2014
    Assignee: Novartis AG
    Inventors: Beate Diefenbach-Streiber, Adina Eberth, Braydon Charles Guild, Yong-In Kim, Michael Roguska, Igor Splawski